Benzimidazoles derivatives as Tec kinases family inhibitors
The present invention relates to a novel family of covalent kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the Tec kinase family, particularly ITK, BTK, BMX, Tec and/or RLK. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvate of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof and its use in therapy.
1. A compound of Formula I:
or pharmaceutically acceptable salt, stereoisomer, tautomer, isotope, prodrug, or complex thereof, wherein
R is substituted or unsubstituted thiophenyl;
L is
wherein
ring B 1 is substituted or unsubstituted cycloalkyl
R 1 is hydrogen, lower alkyl or lower cycloalkyl; and
n is 0 or 1;
E is:
wherein
Ra, Rb and Rc are independently hydrogen, halogen, —CN, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocyclyl; or
Ra and Rb taken together with the carbon atoms to which they are attached form a 3- to 8-membered substituted or unsubstituted cycloalkyl ring or form a 3- to 8-membered substituted or unsubstituted heterocyclic ring and Rc is selected as above; or
Rb and Rc taken together with the carbon atom to which they are attached form a 3- to 8-membered substituted or unsubstituted cycloalkyl ring or form a 3- to 8-substituted or unsubstituted membered heterocyclic ring and Ra is selected as above; or
Ra and Rb taken together with the carbon atoms to which they are attached form a triple bond and Rc is selected as above;
wherein L-E is:
X is alkylene, -(alkylene)-NR 2 —, -(alkylene)-NR 3 —, -(alkylene)-O—, —O—, —S—, —S(O) m —, —NR 2 —, —NR 3 —, —C(O)—, —C(O)O—, —C(O)NR 2 —, —C(O)ONR 2 —, or —S(O) m NR 2 —, wherein
R 2 is hydrogen, lower alkyl or lower cycloalkyl;
R 3 is —C(O)R 4 , —C(O)OR 4 or —S(O) m R 4 ;
R 4 is lower alkyl or lower cycloalkyl;
m is 1 or 2; or
X is a bond; and
Y is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl.
2. The compound according to claim 1 , wherein R is
3. The compound according to claim 1 , wherein
R 1 is hydrogen or methyl;
n is 0;
E is:
wherein
Ra, Rb and Rc are independently hydrogen, halogen, —CN, or C 1 to C 3 substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, or substituted or unsubstituted cycloalkyl
4. The compound according to claim 3 , wherein L-E is
5. The compound according to claim 1 , wherein E is
6. The compound according to claim 1 , wherein X—Y is:
(a) —CH 2 —NH—Y, where
Y is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroaralkyl; or
(b) —CH 2 —NR 2 —Y, where
R 2 is hydrogen, lower alkyl or lower cycloalkyl, and;
Y is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroaralkyl; or
(c) —C(O)—NR 2 —Y, where
R 2 is hydrogen, lower alkyl or lower cycloalkyl, and
Y is selected from the group consisting of: hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroaralkyl; or
(d) —NR 2 C(O)—Y, where
R 2 is hydrogen, lower alkyl or lower cycloalkyl and;
Y is selected from the group consisting of: hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroaralkyl; or
(e) —NR 2 SO 2 —Y, where
R 2 is hydrogen, lower alkyl or lower cycloalkyl, and
Y is selected from the group consisting of: hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroaralkyl; or
(f) —O—CH 2 —Y, where
Y is selected from the group consisting of: hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroaralkyl; or
(g) —CH 2 —NR 3 —Y, where
R 3 is —C(O)R 4 , —C(O)OR 4 or —S(O) m R 4 , wherein m is an integer from 1 to 2;
R 4 is lower alkyl or lower cycloalkyl; and
Y is selected from the group consisting of: hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroaralkyl; or
(h) —CH 2 —Y where
Y is selected from the group consisting of: hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroaralkyl.
7. A compound of Formula IIa:
or pharmaceutically acceptable salt, stereoisomer, tautomer, isotope, prodrug, or complex thereof, wherein
R is substituted or unsubstituted thiophenyl;
X-Y is selected —CH 2 —NH—Y, —CH 2 —NR 2 —Y, —CH 2 —NR 3 —Y, —NR 2 C(O)—Y, —C(O)NR 2 —Y, or and —CH 2 —Y;
wherein
R 2 is hydrogen, lower alkyl or lower cycloalkyl;
R 3 is —C(O)R 4 , —C(O)OR 4 or —S(O) m R 4 , wherein m is 1 or 2;
R 4 is lower alkyl or lower cycloalkyl;
Y is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl,
n 1 is 0, 1, 2 or 3;
n 2 is 1, 2 or 3; and
R 1 is hydrogen, lower alkyl or lower cycloalkyl.
8. A compound having one of the following structures:
Compound
Structure
1
3
6
18
58
62
63
64
65
68
70
71
81
or a pharmaceutically acceptable salt, stereoisomer, tautomer, isotope, prodrug, or complex thereof.
9. A pharmaceutical composition comprising the compound of any one of claim 1 , 2 , 3 , 4 , 5 , 6 , 7 , or 8 , or a pharmaceutically acceptable salt, solvate, solvates of a salt, stereoisomer, tautomer, isotope, prodrug, or complex thereof in combination with at least one pharmaceutically acceptable carrier.
10. A probe comprising the compound of claim 1 covalently conjugated to a detectable label or affinity tag for said compound, wherein the detectable label is optionally selected from the group consisting of: a fluorescent moiety, a chemiluminescent moiety, a paramagnetic contrast agent, a metal chelate, a radioactive isotope-containing moiety and biotin.